Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $3.6 million.

  • Theravance Biopharma's Profit After Tax rose 12846.91% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.3 million, marking a year-over-year increase of 15939.96%. This contributed to the annual value of -$56.4 million for FY2024, which is 221.95% down from last year.
  • As of Q3 2025, Theravance Biopharma's Profit After Tax stood at $3.6 million, which was up 12846.91% from $54.8 million recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's Profit After Tax peaked at $916.6 million during Q3 2022, and registered a low of -$86.5 million during Q1 2021.
  • Over the past 5 years, Theravance Biopharma's median Profit After Tax value was -$15.5 million (recorded in 2024), while the average stood at $26.4 million.
  • In the last 5 years, Theravance Biopharma's Profit After Tax soared by 173947.59% in 2022 and then tumbled by 10097.64% in 2023.
  • Over the past 5 years, Theravance Biopharma's Profit After Tax (Quarter) stood at -$57.8 million in 2021, then skyrocketed by 75.34% to -$14.3 million in 2022, then surged by 40.31% to -$8.5 million in 2023, then crashed by 82.46% to -$15.5 million in 2024, then skyrocketed by 123.28% to $3.6 million in 2025.
  • Its Profit After Tax stands at $3.6 million for Q3 2025, versus $54.8 million for Q2 2025 and -$13.6 million for Q1 2025.